Salbutamol /mL

PreclinicalSmall molecule

MMcMaster University

Salbutamol /mL is one of 7 small molecule programs targeting Allergic Asthma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Allergic AsthmaActive, not recruiting

Allergic AsthmaPreclinical

Active, not recruiting

Competition

Competitive Landscape

9 competitors in Allergic Asthma

#DrugCompanyPhaseTrials

Arcoxia

Novartis

Preclinical

1 2

JYB1904

JJemincare

Phase 2

1 3

FB825

OOneness Biotech Co., Ltd.

Phase 2

1 4

Serevent

GGlaxo Dba Glaxosmithkline

Preclinical

—5

Kenalog

BBausch Health Americas, Inc.

Singulair

Salbutamol /mL

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Allergic Asthma1 trial

Mannitol-Induced Cough Challenge in Healthy Controls and Subjects With Mild Allergic Asthma

Completed·MMcMaster University·N/A·NCT03620422·40 enrolled

Cough1 trial

The Effects of Salbutamol on Mannitol Induced Cough Responses in Healthy Controls

Completed·MMcMaster University·Phase 2·NCT04565847·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Salbutamol /mL. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Salbutamol /mL compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Salbutamol /mL. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — McMaster University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: MMcMaster University

Salbutamol /mL

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Allergic Asthma1 trial

Cough1 trial

References

Drug Info

Quick Facts

Related News